A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first. It can halt the blood cancer myeloma for nearly three times longer ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

Vice Chancellor Morgan T. Zurn for the second time found Alexion liable to Shareholder Representative Services, the Quinn ...

After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. research site and ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...

ADC Therapeutics (NYSE:ADCT), on Thursday, reported results from an early stage trial testing its antibody drug conjugate, ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

The protein language model is trained solely on paired human antibody sequences with scalable applications in antibody ...

MacroGenics' recent royalty deal extends cash runway, but liquidity concerns remain, and further asset sales or dilution may ...